Kai-Uwe Saum1, Ben Schöttker1,2, Andreas D Meid3, Bernd Holleczek4, Walter E Haefeli3, Klaus Hauer2,5, Hermann Brenner1,2. 1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Heidelberg, Germany. 2. Network Aging Research, , University of Heidelberg, Heidelberg, Germany. 3. Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany. 4. Saarland Cancer Registry, Saarbrücken, Germany. 5. Department of Geriatric Research, Bethanien-Hospital and Geriatric Centre, University of Heidelberg, Heidelberg, Germany.
Abstract
OBJECTIVES: To investigate the relationship between polypharmacy and frailty. DESIGN: Longitudinal, observational cohort study. SETTING: Saarland, Germany. PARTICIPANTS: 3,058 community-dwelling adults aged between 57 and 84 years. MEASUREMENTS: Frailty was assessed according to the frailty phenotype, described by Fried et al. Polypharmacy and hyperpolypharmacy were defined as the concomitant use of five or more and 10 or more drugs, respectively. We assessed associations between polypharmacy and prevalent and incident frailty within 3 years of follow-up by logistic regression models controlled for multiple potential confounders including comorbidity. Additionally, cubic splines were used to assess dose-response associations. RESULTS: Polypharmacy was reported in 39.1% (n = 1,194), and hyperpolypharmacy in 8.9% (n = 273) of participants. Prevalent frailty was present in 271 (8.9%) participants; 186 (9.3%) of 1,998 non-frail participants with follow-up data became frail within 3 years. After adjustment, polypharmacy and hyperpolypharmacy were associated with prevalent frailty with adjusted odds ratios (95% confidence interval) of 2.30 (1.60-3.31) and 4.97 (2.97-8.32), respectively. Polypharmacy (odds ratio (OR) 1.51 (1.05-2.16)) and hyperpolypharmacy (OR 1.90 (1.10-3.28)) were also independent predictors of incident frailty. Furthermore, there was a moderate exposure-response relationship between the number of medicines and prevalent as well as incident frailty. CONCLUSION: Our study showed that polypharmacy is associated with frailty. Further research should address the potential benefit of reducing of inappropriate polypharmacy and better pharmacotherapeutic management for preventing medication-associated frailty.
OBJECTIVES: To investigate the relationship between polypharmacy and frailty. DESIGN: Longitudinal, observational cohort study. SETTING: Saarland, Germany. PARTICIPANTS: 3,058 community-dwelling adults aged between 57 and 84 years. MEASUREMENTS: Frailty was assessed according to the frailty phenotype, described by Fried et al. Polypharmacy and hyperpolypharmacy were defined as the concomitant use of five or more and 10 or more drugs, respectively. We assessed associations between polypharmacy and prevalent and incident frailty within 3 years of follow-up by logistic regression models controlled for multiple potential confounders including comorbidity. Additionally, cubic splines were used to assess dose-response associations. RESULTS: Polypharmacy was reported in 39.1% (n = 1,194), and hyperpolypharmacy in 8.9% (n = 273) of participants. Prevalent frailty was present in 271 (8.9%) participants; 186 (9.3%) of 1,998 non-frail participants with follow-up data became frail within 3 years. After adjustment, polypharmacy and hyperpolypharmacy were associated with prevalent frailty with adjusted odds ratios (95% confidence interval) of 2.30 (1.60-3.31) and 4.97 (2.97-8.32), respectively. Polypharmacy (odds ratio (OR) 1.51 (1.05-2.16)) and hyperpolypharmacy (OR 1.90 (1.10-3.28)) were also independent predictors of incident frailty. Furthermore, there was a moderate exposure-response relationship between the number of medicines and prevalent as well as incident frailty. CONCLUSION: Our study showed that polypharmacy is associated with frailty. Further research should address the potential benefit of reducing of inappropriate polypharmacy and better pharmacotherapeutic management for preventing medication-associated frailty.
Authors: M Gutiérrez-Valencia; M Izquierdo; M Cesari; Á Casas-Herrero; M Inzitari; N Martínez-Velilla Journal: Br J Clin Pharmacol Date: 2018-05-03 Impact factor: 4.335
Authors: Dana Clarissa Muhlack; Liesa Katharina Hoppe; Christian Stock; Walter E Haefeli; Hermann Brenner; Ben Schöttker Journal: Eur J Clin Pharmacol Date: 2018-08-29 Impact factor: 2.953
Authors: Nicola Veronese; Brendon Stubbs; Marianna Noale; Marco Solmi; Alberto Pilotto; Alberto Vaona; Jacopo Demurtas; Christoph Mueller; Jonathan Huntley; Gaetano Crepaldi; Stefania Maggi Journal: J Am Med Dir Assoc Date: 2017-04-07 Impact factor: 4.669
Authors: A R M Saifuddin Ekram; Robyn L Woods; Joanne Ryan; Sara E Espinoza; Julia F M Gilmartin-Thomas; Raj C Shah; Raaj Mehta; Bharati Kochar; Judy A Lowthian; Jessica Lockery; Suzanne Orchard; Mark Nelson; Michelle A Fravel; Danny Liew; Michael E Ernst Journal: Arch Gerontol Geriatr Date: 2022-03-23 Impact factor: 4.163